Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial

Michael Boehm, J. Butler, G. Filippatos, J. P. Ferreira, S. J. Pocock, A. Abdin, F. Mahfoud, M. Brueckmann, N. D. Gollop, T. Iwata, P. Ponikowski, C. Wanner, F. Zannad, M. Packer, S. D. Anker

Research output: Contribution to journalAbstractpeer-review

Original languageEnglish
Pages (from-to)131-132
Number of pages2
JournalEuropean Journal of Heart Failure
Issue numberS2
Publication statusPublished - 1 Jul 2022
Externally publishedYes

Cite this